PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Antiresorptive drugs - Market size and forecast 2018-2023 • Anabolic drugs - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Market trends PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Amgen Inc. • Eli Lilly and Company • Novartis AG • Pfizer Inc. • Radius Health, Inc. PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global metabolic disorder therapeutics market Exhibit 02: Segments of global metabolic disorder therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: Antiresorptive drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Antiresorptive drugs - Year-over-year growth 2019-2023 (%) Exhibit 21: Anabolic drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Anabolic drugs - Year-over-year growth 2019-2023 (%) Exhibit 23: Market opportunity by product Exhibit 24: Customer landscape Exhibit 25: Market share by geography 2018-2023 (%) Exhibit 26: Geographic comparison Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 28: North America - Year-over-year growth 2019-2023 (%) Exhibit 29: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 30: Europe - Year-over-year growth 2019-2023 (%) Exhibit 31: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Asia - Year-over-year growth 2019-2023 (%) Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 34: ROW - Year-over-year growth 2019-2023 (%) Exhibit 35: Key leading countries Exhibit 36: Market opportunity Exhibit 37: Late-stage pipeline drugs for osteoporosis Exhibit 38: Patent expiry of osteoporosis drugs Exhibit 39: Impact of drivers and challenges Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: Amgen Inc. - Vendor overview Exhibit 46: Amgen Inc. - Business segments Exhibit 47: Amgen Inc. - Organizational developments Exhibit 48: Amgen Inc. - Geographic focus Exhibit 49: Amgen Inc. - Key offerings Exhibit 50: Eli Lilly and Company - Vendor overview Exhibit 51: Eli Lilly and Company - Business segments Exhibit 52: Eli Lilly and Company - Organizational developments Exhibit 53: Eli Lilly and Company - Geographic focus Exhibit 54: Eli Lilly and Company - Segment focus Exhibit 55: Eli Lilly and Company - Key offerings Exhibit 56: Novartis AG - Vendor overview Exhibit 57: Novartis AG - Business segments Exhibit 58: Novartis AG - Organizational developments Exhibit 59: Novartis AG - Geographic focus Exhibit 60: Novartis AG - Segment focus Exhibit 61: Novartis AG - Key offerings Exhibit 62: Pfizer Inc. - Vendor overview Exhibit 63: Pfizer Inc. - Business segments Exhibit 64: Pfizer Inc. - Organizational developments Exhibit 65: Pfizer Inc. - Geographic focus Exhibit 66: Pfizer Inc. - Segment focus Exhibit 67: Pfizer Inc. - Key offerings Exhibit 68: Radius Health, Inc. - Vendor overview Exhibit 69: Radius Health, Inc. - Organizational developments Exhibit 70: Radius Health, Inc. - Key offerings Exhibit 71: Validation techniques employed for market sizing

Amgen Inc. Eli Lilly and Company Novartis AG Pfizer Inc. Radius Health, Inc.